Cancer Treatment News and Research

RSS

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

Researchers from the Mayo Clinic and representatives from IC-MedTech signed a collaborative research agreement with Summa Health System to study the usage of Apatone, a proprietary combination of Vitamin-C and Vitamin-K3.

2 Sep 2011

ACS' Commission on Cancer releases new standards to directly address patient concerns

A patient-centered approach is at the forefront of new accreditation standards for hospital cancer programs released today by the Commission on Cancer (CoC) of the American College of Surgeons.

2 Sep 2011

FDA approves crizotinib for treatment of ALK-positive lung cancer

In a major triumph for personalized medicine, the FDA approved the drug crizotinib for use with the lung cancer type known as ALK-positive.

2 Sep 2011

Engineered virus shows promise in cancer therapy via bloodstream

Scientists have engineered a virus that when injected into the blood, can selectively target cancer cells throughout the body. The virus attacked only tumours, leaving the healthy tissue alone, in a small trial on 23 patients, according to the journal Nature.

2 Sep 2011

Biophysicists discover how to turn body's own resistance to radiation treatment on and off

Radiation can make cancer cells resistant to radio- and chemotherapy. University of Oslo researchers have now figured out how resistance can be switched on and off.

30 Aug 2011

Medical engineers develop sensor chip to monitor cancerous tumors

A surgery is usually one of the first therapy options in cancer treatment. However, some tumors, such as brain tumors, can be difficult to operate on if there is a risk of damaging surrounding nerve tissue.

29 Aug 2011

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.

29 Aug 2011

Long-term effects of chemotherapy on women's reproductive health

Current estimates of the impact of chemotherapy on women's reproductive health are too low, according to a University of California, San Francisco (UCSF) study.

26 Aug 2011

MDxHealth first half 2011 commercial revenues increase 19%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today its 2011 half-year results.

25 Aug 2011

KU professor to create patient-friendly lung cancer treatment

A Kansas State University professor is trying to create a patient-friendly treatment to help the more than 220,000 people who are diagnosed with lung cancer each year.

23 Aug 2011

Helsinn begins enrollment in anamorelin Phase III trial for NSCLC-associated anorexia/cachexia

Helsinn, a Swiss-based pharmaceutical company, announced today that its US subsidiary, Helsinn Therapeutics, has enrolled the first patient in the company's pivotal Phase III clinical program of anamorelin HCl for the treatment of anorexia/cachexia in patients with advanced non-small cell lung cancer.

23 Aug 2011

IsoRay Cs-131 mesh brachytherapy with da Vinci Robot for lung cancer treatment gains momentum

IsoRay, Inc. said today that a growing number of hospitals and medical treatment centers are adopting its proprietary mesh Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy) for use in conjunction with the da Vinci® Surgical System to treat early stage lung cancer patients. One of the most recent adopters is Georgia's Archbold Memorial Hospital.

23 Aug 2011

Samaritan Medical Center selects ProVation Order Sets electronic solution

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Samaritan Medical Center has selected ProVation® Order Sets, powered by UpToDate® Decision Support, as the organization's electronic order set solution.

23 Aug 2011

Scientists reveal how thiostrepton blocks FOXM1 protein, prevents breast cancer development

Scientists have discovered how a molecule that was first discovered in bacteria blocks a protein which causes breast cancer to develop and spread, reveals research published in Nature Chemistry today.

22 Aug 2011

Wistar Institute, Graham Cancer Center enter research collaboration

Christiana Care Health System's Helen F. Graham Cancer Center and The Wistar Institute, an international leader in biomedical research, have entered into an historic partnership to collaborate on translational cancer research with the aim of bringing the latest discoveries in cancer research to cancer patients in the community.

20 Aug 2011

Semaphorin-PlexinD1 signaling pathway shows promise as therapeutic target for cancer treatment

In a new study published in the August 16th issue of Developmental Cell, researchers at NYU Langone Medical Center identified a molecular mechanism that guarantees that new blood vessels form in the right place and with the proper abundance.

17 Aug 2011

Curis initiates CUDC-101 Phase I combination trial in advanced head and neck cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the first patient has been treated in a Phase I combination trial of CUDC-101.

17 Aug 2011

Scientists define relationship between two prostate tumor suppressor genes

Of the 250,000 American men who will be diagnosed with prostate cancer this year, very few of them-about 1 percent-will develop lethal, metastatic disease. Finding a way to distinguish between this small cohort and the majority of patients who will develop an indolent, non-lethal form of prostate cancer is a key goal in prostate cancer research.

16 Aug 2011

New system could improve prostate cancer IMRT treatment plans

Prostate cancer, the most common form of cancer in U.S. men, is also one of the most treatable: 90 percent of patients who undergo intensity modulated radiation therapy (IMRT) in the early stages are disease free after five years, according to the journal Seminars in Radiation Oncology.

16 Aug 2011

‘Methyl magnet’ genes can cause family cancer risk

Medical researchers have discovered a new type of mechanism causing cancer susceptibility, showing that tiny changes in some anti-cancer genes can act as magnets to attract modifying “biochemical tags”, effectively switching them off and predisposing families to an increased risk of the disease.

15 Aug 2011

Cancer Treatment News and Research

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

ACS' Commission on Cancer releases new standards to directly address patient concerns

FDA approves crizotinib for treatment of ALK-positive lung cancer

Engineered virus shows promise in cancer therapy via bloodstream

Biophysicists discover how to turn body's own resistance to radiation treatment on and off

Medical engineers develop sensor chip to monitor cancerous tumors

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Long-term effects of chemotherapy on women's reproductive health

MDxHealth first half 2011 commercial revenues increase 19%

KU professor to create patient-friendly lung cancer treatment

Helsinn begins enrollment in anamorelin Phase III trial for NSCLC-associated anorexia/cachexia

IsoRay Cs-131 mesh brachytherapy with da Vinci Robot for lung cancer treatment gains momentum

Samaritan Medical Center selects ProVation Order Sets electronic solution

Scientists reveal how thiostrepton blocks FOXM1 protein, prevents breast cancer development

Wistar Institute, Graham Cancer Center enter research collaboration

Semaphorin-PlexinD1 signaling pathway shows promise as therapeutic target for cancer treatment

Curis initiates CUDC-101 Phase I combination trial in advanced head and neck cancer

Scientists define relationship between two prostate tumor suppressor genes

New system could improve prostate cancer IMRT treatment plans

‘Methyl magnet’ genes can cause family cancer risk

Cancer Research eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News